Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website

10 Sep 2018

Oxurion NV trading under “OXUR” on Euronext Brussels
Oxurion NV launches new global website showcasing its comprehensive drug development approach and diverse portfolio of next-generation therapies for back of the eye disease

Leuven, Belgium, 10 September 2018 – Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the start of today’s trading under “OXUR” on Euronext Brussels.

Effective today, the launch of a new ticker and website ( coincides with the company’s name change and highlights its comprehensive approach and renewed focus on the development of best-in-class therapies for back of the eye disorders.

“In light of our recent developments and rebranding program, the launch of the new website reaffirms our commitment to develop disease-modifying therapies for patients living with disorders affecting the back of the eye,” said Patrik De Haes, M.D., CEO of Oxurion. “This comes at an exciting time as we have made great strides with our clinical developments and we look forward to continuing our work to preserve vision for patients around the world by leveraging our deep scientific knowledge of diseases affecting the back of the eye.”


Press release attachment: